Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a ...

Novartis has added another non-alcoholic steatohepatitis (NASH) drug candidate to its pipeline via an $80 million licensing deal with US biotech Pliant ... with obesity, diabetes and high ...

Pliant Therapeutics (NASDAQ:PLRX) stock jumped 28% on Thursday after the company issued an update for a Phase 2b clinical study of bexotegrast in patients with idiopathic pulmonary fibrosis, or ...

The move by Pliant Therapeutics Inc. (Nasdaq: PLRX) of South San Francisco and the response by Wall Street is indicative of the highwire walked by drug developers amid a four-year slowdown in ...